Status:

TERMINATED

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

Lead Sponsor:

Allergan

Conditions:

Gastroparesis

Diabetes Mellitus

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either conti...

Eligibility Criteria

Inclusion

  • Participants are eligible to be included in the study only if all the following criteria apply:
  • Participant met all inclusion/exclusion criteria of either Protocol RLM-MD-01 (NCT03285308) or Protocol RLM-MD-02 (NCT03426345) and successfully completed the study
  • Able to provide written informed consent (IC) prior to any study procedures and willing and able to comply with study procedures
  • In the opinion of the investigator, the participant demonstrated adequate compliance with the study procedures in Study RLM-MD-01 or RLM-MD-02

Exclusion

  • Participants are excluded from the study if any of the following criteria apply:
  • Participant is not willing or able to abide by the restrictions regarding concomitant medicine use
  • Participant is planning to receive an investigational drug (other than study treatment) or investigational device at any time during Study RLM-MD-03
  • Participant has an unresolved adverse event (AE) or a clinically significant finding on physical examination, clinical laboratory test, or 12-lead electrocardiogram (ECG) that, in the investigator's opinion, would limit the participant's ability to participate in or complete the study
  • Any other reason that, in the investigator's opinion, would confound proper interpretation of the study or expose a participant to unacceptable risk, including renal, hepatic or cardiopulmonary disease

Key Trial Info

Start Date :

January 24 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 30 2020

Estimated Enrollment :

467 Patients enrolled

Trial Details

Trial ID

NCT03420781

Start Date

January 24 2018

End Date

October 30 2020

Last Update

December 22 2021

Active Locations (337)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 85 (337 locations)

1

North Alabama Research Center, LLC

Athens, Alabama, United States, 35611

2

Digestive Health Specialist of the South East

Dothan, Alabama, United States, 36305

3

G & L Research, LLC

Foley, Alabama, United States, 36535

4

Alabama Medical Group, PC

Mobile, Alabama, United States, 36608